$TRAW
Traws Pharma, Inc. Stock $traw

$traw Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000110465914039343 Filed on May 15, 2014

Income Statement

Concept	2014 Q2	2014 Q1	2013 Q4
Revenue	$125.0K	$447.0K	$1.930M
YoY Change	-78.85%	-59.95%	-34.99%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.990M	$4.930M	$4.400M
YoY Change	27.88%	47.16%	62.96%
% of Gross Profit
Research & Development	$12.90M	$14.25M	$12.09M
YoY Change	28.44%	11.7%	14.28%
% of Gross Profit
Depreciation & Amortization	$100.0K	$141.0K	$120.0K
YoY Change	-9.09%	43.88%	33.33%
% of Gross Profit
Operating Expenses	$16.89M	$19.18M	$16.49M
YoY Change	28.3%	19.12%	24.22%
Operating Profit	-$16.76M	-$18.73M	-$14.56M
YoY Change	33.33%	25.0%	41.28%
Interest Expense	$0.00	$20.00K	$1.000K
YoY Change	-100.0%	100.0%
% of Operating Profit
Other Income/Expense, Net	-$19.00K	$1.000K	-$126.0K
YoY Change	-246.15%	-99.21%	-407.32%
Pretax Income	-$16.78M	-$18.72M	-$14.63M
YoY Change	33.58%	26.1%	42.52%
Income Tax	$0.00	$0.00	$3.000K
% Of Pretax Income
Net Earnings	-$16.75M	-$18.68M	-$14.62M
YoY Change	33.36%	25.83%	42.42%
Net Earnings / Revenue	-13402.4%	-4178.75%	-757.25%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.675B	-$1.868B	-$1.462B
COMMON SHARES
Basic Shares Outstanding	21.64M shares	21.64M shares	21.41M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q2	2014 Q1	2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$70.50M	$84.60M	$100.0M
YoY Change	37.7%	25.71%
Cash & Equivalents	$55.50M	$54.62M	$60.01M
Short-Term Investments	$15.00M	$30.00M	$40.00M
Other Short-Term Assets	$337.0K	$520.0K	$449.0K
YoY Change	-71.51%	-80.74%	130.26%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$73.83M	$89.02M	$104.4M
YoY Change	29.41%	27.18%	25.39%
LONG-TERM ASSETS
Property, Plant & Equipment	$609.0K	$557.0K	$626.0K
YoY Change	-16.46%	-7.17%	35.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$12.00K	$12.00K	$12.00K
YoY Change	0.0%	-88.0%	0.0%
Total Long-Term Assets	$746.0K	$694.0K	$763.0K
YoY Change	-13.86%	-13.25%	27.17%
TOTAL ASSETS
Total Short-Term Assets	$73.83M	$89.02M	$104.4M
Total Long-Term Assets	$746.0K	$694.0K	$763.0K
Total Assets	$74.57M	$89.72M	$105.2M
YoY Change	28.77%	26.72%	25.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.027M	$3.302M	$3.710M
YoY Change	13.99%	-21.38%	-32.75%
Accrued Expenses	$6.400M	$7.600M	$5.500M
YoY Change	20.75%	35.71%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.95M	$11.56M	$10.34M
YoY Change	-10.22%	-59.02%	-59.26%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.000K	$3.000K	$6.000K
YoY Change	-95.74%	-99.98%	-86.36%
Total Long-Term Liabilities	$2.000K	$3.000K	$6.000K
YoY Change	-95.74%	-99.98%	-86.36%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.95M	$11.56M	$10.34M
Total Long-Term Liabilities	$2.000K	$3.000K	$6.000K
Total Liabilities	$25.63M	$25.35M	$24.25M
YoY Change	-6.76%	-40.34%	-40.62%
SHAREHOLDERS EQUITY
Retained Earnings	-$266.3M	-$249.6M	-$230.9M
YoY Change	36.05%		37.15%
Common Stock	$314.8M	$313.5M	$311.3M
YoY Change	1280.12%		2998.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$48.52M	$63.91M	$80.41M
YoY Change
Total Liabilities & Shareholders Equity	$74.57M	$89.72M	$105.2M
YoY Change	28.77%	26.72%	25.4%

Cashflow Statement

Concept	2014 Q2	2014 Q1	2013 Q4
OPERATING ACTIVITIES
Net Income	-$16.75M	-$18.68M	-$14.62M
YoY Change	33.36%	25.83%	42.42%
Depreciation, Depletion And Amortization	$100.0K	$141.0K	$120.0K
YoY Change	-9.09%	43.88%	33.33%
Cash From Operating Activities	-$14.02M	-$16.17M	-$17.13M
YoY Change	-11.99%	15.91%	-38.2%
INVESTING ACTIVITIES
Capital Expenditures	-$150.0K	$72.00K	-$90.00K
YoY Change	-21.05%	-74.65%	-40.0%
Acquisitions
YoY Change
Other Investing Activities	$15.00M	$10.00M	$0.00
YoY Change
Cash From Investing Activities	$14.85M	$9.930M	-$90.00K
YoY Change	-7915.79%	-3646.43%	-40.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	50.00K	850.0K	600.0K
YoY Change		8400.0%	-52.0%
NET CHANGE
Cash From Operating Activities	-14.02M	-16.17M	-17.13M
Cash From Investing Activities	14.85M	9.930M	-90.00K
Cash From Financing Activities	50.00K	850.0K	600.0K
Net Change In Cash	880.0K	-5.390M	-16.62M
YoY Change	-105.46%	-62.1%	-37.57%
FREE CASH FLOW
Cash From Operating Activities	-$14.02M	-$16.17M	-$17.13M
Capital Expenditures	-$150.0K	$72.00K	-$90.00K
Free Cash Flow	-$13.87M	-$16.24M	-$17.04M
YoY Change	-11.88%	14.11%	-38.19%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q2	ontx	Number Of Clinical Programs Developed NumberOfClinicalProgramsDeveloped	2	item
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-18679000	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-249575000	USD
CY2014Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2014Q1	ontx	Number Of Series Denominations Of Preferred Stock NumberOfSeriesDenominationsOfPreferredStock	10	item
CY2013Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	626000	USD
CY2014Q1	ontx	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	5808000	USD
CY2013Q4	ontx	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	4625000	USD
CY2014Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1383000	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	509000	USD
CY2014Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	329000	USD
CY2014Q1	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2013Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2014Q1	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0	USD
CY2013Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0	USD
CY2014Q1	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0	USD
CY2013Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0	USD
CY2014Q1	ontx	Prepaid Research And Development Current PrepaidResearchAndDevelopmentCurrent	2435000	USD
CY2013Q4	ontx	Prepaid Research And Development Current PrepaidResearchAndDevelopmentCurrent	2242000	USD
CY2014Q1	ontx	Prepaid Manufacturing PrepaidManufacturing	1025000	USD
CY2013Q4	ontx	Prepaid Manufacturing PrepaidManufacturing	1051000	USD
CY2014Q1	us-gaap	Prepaid Insurance PrepaidInsurance	421000	USD
CY2013Q4	us-gaap	Prepaid Insurance PrepaidInsurance	645000	USD
CY2014Q1	us-gaap	Other Assets Current OtherAssetsCurrent	520000	USD
CY2014Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	item
CY2014Q1	ontx	Number Of Group Companies Of Which Average Historical Share Price Trading Data Used For Estimation Of Volatility NumberOfGroupCompaniesOfWhichAverageHistoricalSharePriceTradingDataUsedForEstimationOfVolatility	11	item
CY2014Q1	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2013Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4256768	shares
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15634893	shares
CY2013Q4	us-gaap	Other Assets Current OtherAssetsCurrent	449000	USD
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4401000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4387000	USD
CY2014Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2471000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2402000	USD
CY2014Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1914000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1776000	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	557000	USD
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	310000	USD
CY2014Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	208000	USD
CY2013Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	302000	USD
CY2014Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	67000	USD
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	74000	USD
CY2014Q1	ontx	Accrued Expenses And Other Current Liabilities Current AccruedExpensesAndOtherCurrentLiabilitiesCurrent	7795000	USD
CY2013Q4	ontx	Accrued Expenses And Other Current Liabilities Current AccruedExpensesAndOtherCurrentLiabilitiesCurrent	5820000	USD
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1328000	USD
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2465000	USD
CY2013Q3	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	79811000	USD
CY2013Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.75	pure
CY2013Q3	ontx	Designated Public Offering Amended Threshold Gross Proceeds Minimum DesignatedPublicOfferingAmendedThresholdGrossProceedsMinimum	25000000	USD
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	Onconova Therapeutics, Inc.
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001130598
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	21640387	shares
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54624000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60009000	USD
CY2014Q1	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	29999000	USD
CY2013Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	39994000	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	89024000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	104390000	USD
CY2014Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	125000	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	125000	USD
CY2014Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	12000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	12000	USD
CY2014Q1	us-gaap	Assets Assets	89718000	USD
CY2013Q4	us-gaap	Assets Assets	105153000	USD
CY2014Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3302000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3710000	USD
CY2014Q1	ontx	Warrant Liability Current WarrantLiabilityCurrent	4000	USD
CY2013Q4	ontx	Warrant Liability Current WarrantLiabilityCurrent	20000	USD
CY2014Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	455000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	788000	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	11556000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10338000	USD
CY2014Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	13795000	USD
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	13909000	USD
CY2014Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6000	USD
CY2014Q1	us-gaap	Liabilities Liabilities	25354000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	24253000	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2014Q1	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	217000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	215000	USD
CY2014Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	313272000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	311093000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-230896000	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	63914000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	80413000	USD
CY2014Q1	us-gaap	Minority Interest MinorityInterest	450000	USD
CY2013Q4	us-gaap	Minority Interest MinorityInterest	487000	USD
CY2014Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	64364000	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	80900000	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	89718000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	105153000	USD
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21638887	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21638887	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21467482	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21467482	shares
CY2014Q1	us-gaap	Revenues Revenues	447000	USD
CY2013Q1	us-gaap	Revenues Revenues	1116000	USD
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4932000	USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3346000	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14248000	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12756000	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	19180000	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	16102000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-18733000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14986000	USD
CY2014Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-16000	USD
CY2013Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-14000	USD
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1000	USD
CY2013Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	127000	USD
CY2014Q1	us-gaap	Profit Loss ProfitLoss	-18716000	USD
CY2013Q1	us-gaap	Profit Loss ProfitLoss	-14845000	USD
CY2014Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-37000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-14845000	USD
CY2013Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	1019000	USD
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18679000	USD
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15864000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.87
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-6.08
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21568302	shares
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2607406	shares
CY2014Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	7000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	7000	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18717000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14838000	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-37000	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-18680000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-14838000	USD
CY2014Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	853000	USD
CY2014Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1328000	USD
CY2014Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	141000	USD
CY2013Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	98000	USD
CY2014Q1	ontx	Treasury Note Discount Amortization TreasuryNoteDiscountAmortization	-5000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1328000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2465000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	14000	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	941000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-408000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1274000	USD
CY2014Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1975000	USD
CY2013Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1634000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-3000	USD
CY2013Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	20000	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-447000	USD
CY2013Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1092000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-16165000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-13949000	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	72000	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	284000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	9928000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-284000	USD
CY2014Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	853000	USD
CY2013Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	853000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	6000	USD
CY2014Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-1000	USD
CY2013Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	7000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-5385000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-14220000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	67307000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81527000	USD
CY2014Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">1. Nature of Business</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">The Company</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 25pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Onconova Therapeutics, Inc. (the “Company”) was incorporated in the State of Delaware on December 22, 1998 and commenced operations on January 1, 1999. The Company’s headquarters are located in Newtown, Pennsylvania. The Company is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using its proprietary chemistry platform, the Company has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. The Company believes that the drug candidates in its pipeline have the potential to be efficacious in a wide variety of cancers without causing harm to normal cells. The Company has three clinical-stage product candidates and six preclinical programs. To accelerate and broaden the development of rigosertib, the Company’s most advanced product candidate, the Company entered into a collaboration and license agreement in 2012 with Baxter Healthcare SA (“Baxter”), a subsidiary of Baxter International Inc., to commercialize rigosertib in Europe. In 2011, the Company entered into a collaboration and license agreement with SymBio Pharmaceuticals Limited (“SymBio”) to commercialize rigosertib in Japan and Korea. The Company has retained development and commercialization rights to rigosertib in the rest of the world, including the United States. During 2012, Onconova Europe GmbH was established as a wholly owned subsidiary of the Company for the purpose of further developing business in Europe. In April 2013, GBO, LLC, a Delaware limited liability company, (“GBO”) was formed pursuant to a collaboration agreement with GVK Biosciences Private Limited, a private limited company located in India, (“GVK BIO”) to collaborate and develop two new clinical programs using the Company’s technology platform.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Liquidity</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 26pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company has incurred recurring operating losses since inception. For the three months ended March 31, 2014, the Company incurred a net loss of $18,716,000 and as of March 31, 2014, the Company had generated an accumulated deficit of $249,575,000. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to research funding, development of its product candidates and its preclinical programs, strategic alliances and the development of its administrative organization. The Company will require substantial additional financing to continue to fund its operations and execute its strategy.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 22pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Since its inception, the Company raised significant capital through the issuance of redeemable convertible preferred stock, par value $0.01 per share, in ten series denominated as Series A through Series J (“Series A Preferred Stock” through “Series J Preferred Stock,” respectively, and collectively the “Preferred Stock”).  On July 30, 2013, the Company completed its initial public offering (the “IPO”) of 5,941,667 shares of the Company’s common stock, par value $0.01 per share (“Common Stock”), at a price of $15.00 per share, including 775,000 shares of Common Stock issued upon the exercise in full by the underwriters of their option to purchase additional shares at the same price to cover over-allotments. The Company received net proceeds of $79,811,000 from the sale, net of underwriting discounts and commissions and other estimated offering expenses. Immediately prior to the consummation of the IPO, all outstanding shares of Preferred Stock automatically converted into shares of Common Stock at the applicable conversion ratio then in effect.  As a result of the conversion, as of July 30, 2013, the Company had no shares of Preferred Stock outstanding.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 26pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company’s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its research and development and commercial programs and meet its obligations. Management intends to fund future operations through additional equity offerings, licensing revenue, grants, government contracts and, if any of the Company’s product candidates receive marketing approval, future sales of its products. There can be no assurance, however, that the Company will be successful in obtaining financing at the level needed to sustain operations or on terms acceptable to the Company, or that the Company will obtain approvals necessary to market its products or achieve profitability or sustainable, positive cash flow.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> </div>
CY2014Q1	ontx	Employee Service Share Based Compensation Nonvested Liability Awards Total Compensation Cost Not Yet Recognized Period For Recognition EmployeeServiceShareBasedCompensationNonvestedLiabilityAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition	P2Y3M11D
CY2014Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	11043000	USD
CY2014Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	10000000	USD
CY2014Q1	ontx	Employee Service Share Based Compensation Nonvested Liability Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedLiabilityAwardsTotalCompensationCostNotYetRecognized	1559000	USD
CY2014Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y6M7D

Files In Submission

Name	View Source	Status
0001104659-14-039343-index-headers.html	Edgar Link	pending
0001104659-14-039343-index.html	Edgar Link	pending
0001104659-14-039343.txt	Edgar Link	pending
0001104659-14-039343-xbrl.zip	Edgar Link	pending
a14-9793_110q.htm	Edgar Link	pending
a14-9793_1ex31d1.htm	Edgar Link	pending
a14-9793_1ex31d2.htm	Edgar Link	pending
a14-9793_1ex32d1.htm	Edgar Link	pending
a14-9793_1ex32d2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ontx-20140331.xml	Edgar Link	completed
ontx-20140331.xsd	Edgar Link	pending
ontx-20140331_cal.xml	Edgar Link	unprocessable
ontx-20140331_def.xml	Edgar Link	unprocessable
ontx-20140331_lab.xml	Edgar Link	unprocessable
ontx-20140331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TRAW
Traws Pharma, Inc. Stock $traw

2014 Q2 Form 10-Q Financial Statement

#000110465914039343 Filed on May 15, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TRAW Traws Pharma, Inc. Stock $traw

2014 Q2 Form 10-Q Financial Statement

#000110465914039343 Filed on May 15, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TRAW
Traws Pharma, Inc. Stock $traw